Tag Archives: Gilead

Pharma in the Dell: Working with Academia

By Ben Comer | Published: November 14, 2012
How can the emerging field of data science help to fruitfully translate research and discovery into successful drug development? Academics and pharmaceutical executives at Mount Sinai’s School of Medicine discussed ways to build a bridge across the valley of death, and the growing importance of data across all business areas.
Posted in Biotech, Deals, IP, Meetings, People, R&D, Strategy, Technology, leadership | Also tagged , , , , , | Leave a comment

Gilead Tops the BusinessWeek 50

By Patrick Clinton | Published: April 2, 2009
The best-performing company of them all? Well, according to BusinessWeek, it’s a biopharmaceutical company, Gilead Sciences, which placed first in the annual BusinessWeek 50. The company posted some impressive numbers: a 48.6 percent pretax profit as a percentage of average invested capital (taken as an average of the last three years), 38.2 average annual sales [...]
Posted in Strategy | Also tagged | Leave a comment

Gilead Buys CV Therapeutics (Update 1)

By Walter Armstrong | Published: March 16, 2009
The morning’s other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that it will purchase CV Therapeutics for $1.4 billion. The sudden move frees Palo Alto-based cardiovascular company CV Therapeutics from the hostile embrace of Astellas Pharma, ending a messy $1.1 billion takeover attempt. With the acquisition, Gilead, [...]
Posted in Deals | Also tagged , , , , , , | 3 Comments

Gilead Making a Bundle

By Walter Armstrong | Published: February 10, 2009
Gilead Sciences has once again proven that independent biotechs can innovate with the best of Big Pharma. The Silicon Valley company’s wizardry at weaving multiple drugs into a single weft enabled it to overthrow GlaxoSmithKline as king of HIV in 2007. Yesterday, at the 16th annual Congress of Retroviruses and Opportunistic Infections (CROI), the biotech [...]
Posted in Biotech, Emerging Markets, R&D | Also tagged , , | Leave a comment